Trial Profile
Treatment of Respiratory Syncytial Virus Bronchiolitis in Young Infants With Humanized Monoclonal Antibody: A Randomized Clinical Trial (Palivizumab Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2018
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 26 Feb 2018 Status changed from recruiting to completed.
- 28 Aug 2016 Planned number of patients changed from 200 to 420.
- 28 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.